All In Biotech

Drug Trial Radar · NCT00946920

A Trial of Degarelix in Patients With Prostate Cancer

An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen With Goserelin Acetate in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy

Last checked: Nov 19, 2026Latest source record: Jun 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 859 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

859

Actual

Start

Jun 2009

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • DegarelixDrug

    The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).

  • Goserelin acetateDrug

    The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) With DegarelixTime frame: From Day 28 to Day 364
  2. Difference in Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) Between Degarelix and GoserelinTime frame: Day 3 to Day 364

Locations

126 sites in 14 countries. Site status is shown where the registry gives one.

  • Urology Centers Of Alabama

    Homewood, Alabama

  • Arkansas Urology

    Little Rock, Arkansas

  • Urology Associates of Central CA

    Fresno, California

  • Medresearch

    La Mesa, California

  • South Orange County Medical Research Center

    Laguna Hills, California

  • Atlantic Urology Medical Group

    Long Beach, California

  • Anschutz Cancer Pavillion

    Aurora, Colorado

  • The Urology Center of Colorado

    Denver, Colorado

  • Urological Associates of Bridgeport, P.C.

    Trumbull, Connecticut

  • Urology Associates of Dover, PA

    Dover, Delaware

  • Walter Reed Army Medical Center

    Washington D.C., District of Columbia

  • South Florida Medical Research

    Aventura, Florida

  • Florida Foundation for Healthcare Research

    Ocala, Florida

  • Georgis Patsias, MD, PA

    Wellington, Florida

  • Palm Beach Urology Associates, PA

    Wellington, Florida

  • Indiana University Department of Urology

    Indianapolis, Indiana

  • Kansas City Urology Care, PA

    Overland Park, Kansas

  • Urological Associates of Englewood

    Englewood, New Jersey

  • Hamilton Urology PA

    Hamilton, New Jersey

  • Lawrenceville Urology

    Lawrenceville, New Jersey

  • Urology Group of New Mexico, PC

    Albuquerque, New Mexico

  • Capital Region Urological Surgeons and Research Associates

    Albany, New York

  • Hudson Valley Urology P.C.

    Poughkeepsie, New York

  • Metrolina Urology Clinic

    Charlotte, North Carolina

  • Northeast Urology Research

    Concord, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Alliance Urology Specialists

    Greensboro, North Carolina

  • Urologic Consultants of SEPA

    Bala-Cynwyd, Pennsylvania

  • State College Urologic Association

    State College, Pennsylvania

  • Grand Strand Urology

    Myrtle Beach, South Carolina

  • Urology Clinics of North Texas, PA

    Dallas, Texas

  • Urology San Antonio Research

    San Antonio, Texas

  • Urology of Virginia

    Norfolk, Virginia

  • Virginia Urology Center

    Richmond, Virginia

  • Urology of Virginia

    Virginia Beach, Virginia

  • Seattle Urology Research Center

    Burien, Washington

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • UZ Gent

    Ghent, Belgium

  • AZ Groeninge - Campus Sint-Maarten

    Kortrijk, Belgium

Showing 40 of 126 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.